Thirteen Finalists Chosen for Boehringer Ingelheim and Ashoka Changemakers "Making More Health" Competition

Boehringer IngelheimBoehringer Ingelheim and Ashoka Changemakers announced that thirteen finalists have been selected in the first Boehringer Ingelheim Making More Health competition. The online competition is part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world. The public is now invited to vote to determine the competition's three winners, who will each receive a $10,000 (US) cash prize to help further their idea.

The finalists, selected from more than 470 entries received, represent the most innovative and promising solutions from around the globe that are transforming the field of health. Finalists were selected by the competition's panel of expert judges, which included Aman Bhandari of the U.S. Department of Health and Human Services, Carol A. Dahl, executive director of The Lemelson Foundation, and Andreas Barner, Chairman of the Board of Managing Directors for Boehringer Ingelheim.

The goal of the Making More Health competition is to identify and support innovations with the potential to shape the future of the health sector for the benefit of individuals, families, and communities. Entries addressed a broad range of health and healthcare challenges from prevention and lifestyle, to detection and treatment. The 13 finalists represent the most innovative solutions for improving health systems in these areas.

"The Making More Health competition reflects Boehringer Ingelheim’s commitment to supporting leadership and innovation in healthcare and to improving health for individuals, families, and communities," said Jean Scheftsik de Szolnok, Vice-President Southern Europe for Boehringer Ingelheim. "By identifying and supporting new approaches to healthcare delivery we are helping to ensure a sustainable future in which good health for everyone is possible."

The finalists in the first Making More Health competition are:

  • Affordable, Quality Health Care and Services for the Underprivileged, Pakistan
  • ColaLife: Piggybacking Simple Medicines on Cola Supply Chains, to Save Lives in Underserved Rural areas in Africa, Zambia
  • Cool2Care - Tackling Disability by Connecting Young Curers with Families in Need, United Kingdom
  • eDOTS: Demanding Reliable Results from Tuberculosis Treatment, India
  • E HealthPoint Transforming Rural Healthcare, India
  • A Life-Saving Diagnosis: Sample Transport, Reducing the Time Delay in Monitoring and Diagnosing HIV and TB, Lesotho
  • miraclefeet: Preventing Unnecessary Disability Caused by Untreated Clubfoot Around the World, United States
  • Pathways to Wellness: Integrating Refugee Health and Well-Being, United States
  • RevoLOOtionary: Developing Rural Markets for Sanitation, Cambodia
  • SMS Now! A Life Depends on It, India
  • Saúde Criança: Holistic Health Solutions for Families in Favelas, Brazil
  • Sustainable Sanitation in Urban Slums: The Path to Permanently Reducing Sanitation-Related Disease, Kenya
  • Unite For Sight, Ghana

The public can vote at www.changemakers.com/morehealth and from the Changemakers Facebook page between November 9 and November 30, 2011. Winners will be announced on December 7, 2011.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.In 2010, Boehringer Ingelheim posted net sales of 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

About Ashoka Changemakers
Ashoka Changemakers is an online community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and scaling-up ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and vision for an "Everyone a Changemaker" world by creating a place where the best ideas in social innovation can be shared, refined, and funded.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...